10-QPeriod: Q2 FY1996

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 1996

Filed August 14, 1996For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb Co. (BMY) filed its Form 10-Q for the quarterly period ending June 29, 1996. This filing provides a snapshot of the company's financial performance and position during this period. Investors should note that as this is a historical filing from 1996, it reflects a business environment and product landscape significantly different from today. The information presented is crucial for understanding the company's historical trajectory and can be used as a baseline for evaluating its long-term growth and strategic decisions made in the mid-1990s. While specific financial metrics and segment performance details are not provided in the provided filing excerpt, typical 10-Q filings would include detailed financial statements, management's discussion and analysis (MD&A) of financial condition and results of operations, and disclosures on legal proceedings and risk factors. Investors interested in BMY's performance during this quarter would need to access the full report to gain comprehensive insights into revenue, profitability, debt levels, and any significant operational developments.

Key Highlights

  • 1Company: Bristol Myers Squibb Co. (BMY)
  • 2Filing Type: Quarterly Report (10-Q)
  • 3Period End Date: June 29, 1996
  • 4Filing Date: August 13, 1996
  • 5The filing represents a historical financial update from the mid-1990s.
  • 6Specific financial data and operational details are not detailed in the provided excerpt, requiring access to the full report for in-depth analysis.

Frequently Asked Questions

This filing is a Form 10-Q, a quarterly report required by the U.S. Securities and Exchange Commission (SEC). Its purpose is to provide investors with an update on the company's financial performance and position during the specified quarter.

A full 10-Q filing typically includes unaudited interim financial statements (balance sheets, income statements, cash flow statements), management's discussion and analysis (MD&A) of the company's financial condition and results of operations, updates on legal proceedings, and disclosures about any significant changes in internal controls or risk factors.

This 1996 filing is historically significant for understanding Bristol Myers Squibb's past performance and strategic context. However, it is not directly indicative of the company's current financial health or market position, which have evolved considerably over nearly three decades due to product life cycles, acquisitions, divestitures, and market dynamics. It serves as a data point for long-term trend analysis rather than a primary basis for current investment decisions.

To access the complete financial details, including specific revenue figures, profitability, and management's commentary, you would need to locate and review the full Form 10-Q filing for the period ending June 29, 1996, from the SEC's EDGAR database or other financial data providers.